Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Reply.

Hepatology (Baltimore, Md.)

Corpechot C, Dahlqvist G, Chazouillères O, Johanet C.
PMID: 28510367
Hepatology. 2017 Sep;66(3):998. doi: 10.1002/hep.29263. Epub 2017 Jul 27.

No abstract available.

Cite
Corpechot C, Dahlqvist G, Chazouillères O, et al. Reply. Hepatology. 2017;66(3):998doi: 10.1002/hep.29263.
Corpechot, C., Dahlqvist, G., Chazouillères, O., & Johanet, C. (2017). Reply. Hepatology (Baltimore, Md.), 66(3), 998. https://doi.org/10.1002/hep.29263
Corpechot, Christophe, et al. "Reply." Hepatology (Baltimore, Md.) vol. 66,3 (2017): 998. doi: https://doi.org/10.1002/hep.29263
Corpechot C, Dahlqvist G, Chazouillères O, Johanet C. Reply. Hepatology. 2017 Sep;66(3):998. doi: 10.1002/hep.29263. Epub 2017 Jul 27. PMID: 28510367.
Copy Download .nbib Format: NLM
Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?.

Nature clinical practice. Gastroenterology & hepatology

Chazouillères O, Corpechot C.
PMID: 16673001
Nat Clin Pract Gastroenterol Hepatol. 2006 May;3(5):248-9. doi: 10.1038/ncpgasthep0493.

No abstract available.

Cite
Chazouillères O, Corpechot C. Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?. Nat Clin Pract Gastroenterol Hepatol. 2006;3(5):248-9doi: 10.1038/ncpgasthep0493.
Chazouillères, O., & Corpechot, C. (2006). Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?. Nature clinical practice. Gastroenterology & hepatology, 3(5), 248-9. https://doi.org/10.1038/ncpgasthep0493
Chazouillères, Olivier, and Corpechot, Christophe. "Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?." Nature clinical practice. Gastroenterology & hepatology vol. 3,5 (2006): 248-9. doi: https://doi.org/10.1038/ncpgasthep0493
Chazouillères O, Corpechot C. Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?. Nat Clin Pract Gastroenterol Hepatol. 2006 May;3(5):248-9. doi: 10.1038/ncpgasthep0493. PMID: 16673001.
Copy Download .nbib Format: NLM
A World Health Organization Human Hepatitis E Virus Reference Strain Related to Similar Strains Isolated from Rabbits.

Genome announcements

Kaiser M, Delaune D, Chazouillères O, Blümel J, Roque-Afonso AM, Baylis SA.
PMID: 29674549
Genome Announc. 2018 Apr 19;6(16). doi: 10.1128/genomeA.00292-18.

We report here the genome sequence of a hepatitis E virus (HEV) strain from a chronically infected immunodeficient patient. Full-length sequence analysis revealed a distinct HEV strain, of a tentative new subgenotype, clustering with viruses from rabbits. It is...

Cite
Kaiser M, Delaune D, Chazouillères O, et al. A World Health Organization Human Hepatitis E Virus Reference Strain Related to Similar Strains Isolated from Rabbits. Genome Announc. 2018;6(16)doi: 10.1128/genomeA.00292-18.
Kaiser, M., Delaune, D., Chazouillères, O., Blümel, J., Roque-Afonso, A. M., & Baylis, S. A. (2018). A World Health Organization Human Hepatitis E Virus Reference Strain Related to Similar Strains Isolated from Rabbits. Genome announcements, 6(16), . https://doi.org/10.1128/genomeA.00292-18
Kaiser, Marco, et al. "A World Health Organization Human Hepatitis E Virus Reference Strain Related to Similar Strains Isolated from Rabbits." Genome announcements vol. 6,16 (2018). doi: https://doi.org/10.1128/genomeA.00292-18
Kaiser M, Delaune D, Chazouillères O, Blümel J, Roque-Afonso AM, Baylis SA. A World Health Organization Human Hepatitis E Virus Reference Strain Related to Similar Strains Isolated from Rabbits. Genome Announc. 2018 Apr 19;6(16). doi: 10.1128/genomeA.00292-18. PMID: 29674549; PMCID: PMC5908947.
Copy Download .nbib Format: NLM
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.

Clinics and research in hepatology and gastroenterology

Vallet-Pichard A, Correas JM, Dorival C, Zoulim F, Tran A, Bourlière M, Calès P, Guyader D, Bronowicki JP, Larrey D, Hezode C, Loustaud-Ratti V, Gournay J, de Ledinghen V, Asselah T, Ganne N, Metivier S, Chazouillères O, Leroy V, Rosa I, Samuel D, Mathurin P, Cagnot C, Fontaine H, Carrat F, Pol S.
PMID: 32595103
Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101459. doi: 10.1016/j.clinre.2020.04.022. Epub 2020 Jun 25.

BACKGROUND: Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth is still a subject of debate. We...

Cite
Vallet-Pichard A, Correas JM, Dorival C, et al. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clin Res Hepatol Gastroenterol. 2020;45(1):101459doi: 10.1016/j.clinre.2020.04.022.
Vallet-Pichard, A., Correas, J. M., Dorival, C., Zoulim, F., Tran, A., Bourlière, M., Calès, P., Guyader, D., Bronowicki, J. P., Larrey, D., Hezode, C., Loustaud-Ratti, V., Gournay, J., de Ledinghen, V., Asselah, T., Ganne, N., Metivier, S., Chazouillères, O., Leroy, V., Rosa, I., Samuel, D., Mathurin, P., Cagnot, C., Fontaine, H., Carrat, F., Pol, S. (2021). Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clinics and research in hepatology and gastroenterology, 45(1), 101459. https://doi.org/10.1016/j.clinre.2020.04.022
Vallet-Pichard, Anais, et al. "Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort." Clinics and research in hepatology and gastroenterology vol. 45,1 (2021): 101459. doi: https://doi.org/10.1016/j.clinre.2020.04.022
Vallet-Pichard A, Correas JM, Dorival C, Zoulim F, Tran A, Bourlière M, Calès P, Guyader D, Bronowicki JP, Larrey D, Hezode C, Loustaud-Ratti V, Gournay J, de Ledinghen V, Asselah T, Ganne N, Metivier S, Chazouillères O, Leroy V, Rosa I, Samuel D, Mathurin P, Cagnot C, Fontaine H, Carrat F, Pol S. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101459. doi: 10.1016/j.clinre.2020.04.022. Epub 2020 Jun 25. PMID: 32595103.
Copy Download .nbib Format: NLM
Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium.

European journal of gastroenterology & hepatology

Pariente A, Chazouilleres O, Causse X, Hanslik B, Arpurt JP, Henrion J, Rosa I, Renou C, Garioud A, Corpechot C.
PMID: 33252413
Eur J Gastroenterol Hepatol. 2020 Nov 30; doi: 10.1097/MEG.0000000000002011. Epub 2020 Nov 30.

BACKGROUND AND AIMS: To assess the characteristics, care, treatment response, and outcomes of primary biliary cholangitis (PBC) patients recently followed-up by hepato-gastroenterologists in various French and Belgian healthcare settings.METHODS: This retrospective cohort study included patients with PBC who recently...

Cite
Pariente A, Chazouilleres O, Causse X, et al. Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium. Eur J Gastroenterol Hepatol. 2020;doi: 10.1097/MEG.0000000000002011.
Pariente, A., Chazouilleres, O., Causse, X., Hanslik, B., Arpurt, J. P., Henrion, J., Rosa, I., Renou, C., Garioud, A., Corpechot, C. (2020). Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium. European journal of gastroenterology & hepatology, . https://doi.org/10.1097/MEG.0000000000002011
Pariente, Alexandre, et al. "Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium." European journal of gastroenterology & hepatology vol. (2020). doi: https://doi.org/10.1097/MEG.0000000000002011
Pariente A, Chazouilleres O, Causse X, Hanslik B, Arpurt JP, Henrion J, Rosa I, Renou C, Garioud A, Corpechot C. Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium. Eur J Gastroenterol Hepatol. 2020 Nov 30; doi: 10.1097/MEG.0000000000002011. Epub 2020 Nov 30. PMID: 33252413.
Copy Download .nbib Format: NLM
Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool.

European journal of gastroenterology & hepatology

Murillo Perez CF, Gulamhusein A, Carbone M, Trivedi PJ, van der Meer AJ, Corpechot C, Battezzati PM, Lammers WJ, Cazzagon N, Floreani A, Parés A, Nevens F, Lleo A, Mayo MJ, Kowdley KV, Ponsioen CY, Dalekos GN, Gatselis NK, Thorburn D, Mason AL, Janssen H, Verhelst X, Bruns T, Lindor KD, Chazouillères O, Invernizzi P, Hansen BE, Hirschfield GM.
PMID: 33323757
Eur J Gastroenterol Hepatol. 2020 Dec 14; doi: 10.1097/MEG.0000000000002029. Epub 2020 Dec 14.

BACKGROUND: Opportunity to redefine the care journeys for those living with primary biliary cholangitis (PBC) includes facilitating access to enhanced (PBC-dedicated) programmes by nonspecialist risk 'flagging' of patients.OBJECTIVE: To develop a nonexpert PBC stratification tool to help care pathway...

Cite
Murillo Perez CF, Gulamhusein A, Carbone M, et al. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. Eur J Gastroenterol Hepatol. 2020;doi: 10.1097/MEG.0000000000002029.
Murillo Perez, C. F., Gulamhusein, A., Carbone, M., Trivedi, P. J., van der Meer, A. J., Corpechot, C., Battezzati, P. M., Lammers, W. J., Cazzagon, N., Floreani, A., Parés, A., Nevens, F., Lleo, A., Mayo, M. J., Kowdley, K. V., Ponsioen, C. Y., Dalekos, G. N., Gatselis, N. K., Thorburn, D., Mason, A. L., Janssen, H., Verhelst, X., Bruns, T., Lindor, K. D., Chazouillères, O., Invernizzi, P., Hansen, B. E., Hirschfield, G. M. (2020). Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. European journal of gastroenterology & hepatology, . https://doi.org/10.1097/MEG.0000000000002029
Murillo Perez, Carla F, et al. "Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool." European journal of gastroenterology & hepatology vol. (2020). doi: https://doi.org/10.1097/MEG.0000000000002029
Murillo Perez CF, Gulamhusein A, Carbone M, Trivedi PJ, van der Meer AJ, Corpechot C, Battezzati PM, Lammers WJ, Cazzagon N, Floreani A, Parés A, Nevens F, Lleo A, Mayo MJ, Kowdley KV, Ponsioen CY, Dalekos GN, Gatselis NK, Thorburn D, Mason AL, Janssen H, Verhelst X, Bruns T, Lindor KD, Chazouillères O, Invernizzi P, Hansen BE, Hirschfield GM. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. Eur J Gastroenterol Hepatol. 2020 Dec 14; doi: 10.1097/MEG.0000000000002029. Epub 2020 Dec 14. PMID: 33323757.
Copy Download .nbib Format: NLM
A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients.

Expert review of gastroenterology & hepatology

Hirschfield GM, Chazouillères O, Cortez-Pinto H, Macedo G, de Lédinghen V, Adekunle F, Carbone M.
PMID: 34233565
Expert Rev Gastroenterol Hepatol. 2021 Aug;15(8):929-939. doi: 10.1080/17474124.2021.1945919. Epub 2021 Jul 07.

INTRODUCTION: Primary biliary cholangitis (PBC) is an infrequent, immune-mediated cholestatic liver disease, which can lead to liver fibrosis, cirrhosis and complications of end-stage liver disease. The established goals of treatment of PBC are prevention of end-stage liver disease and...

Cite
Hirschfield GM, Chazouillères O, Cortez-Pinto H, et al. A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. Expert Rev Gastroenterol Hepatol. 2021;15(8):929-939doi: 10.1080/17474124.2021.1945919.
Hirschfield, G. M., Chazouillères, O., Cortez-Pinto, H., Macedo, G., de Lédinghen, V., Adekunle, F., & Carbone, M. (2021). A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. Expert review of gastroenterology & hepatology, 15(8), 929-939. https://doi.org/10.1080/17474124.2021.1945919
Hirschfield, Gideon M, et al. "A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients." Expert review of gastroenterology & hepatology vol. 15,8 (2021): 929-939. doi: https://doi.org/10.1080/17474124.2021.1945919
Hirschfield GM, Chazouillères O, Cortez-Pinto H, Macedo G, de Lédinghen V, Adekunle F, Carbone M. A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. Expert Rev Gastroenterol Hepatol. 2021 Aug;15(8):929-939. doi: 10.1080/17474124.2021.1945919. Epub 2021 Jul 07. PMID: 34233565.
Copy Download .nbib Format: NLM
Corrigendum.

Alimentary pharmacology & therapeutics

Pol S, Luzivika Nzinga C, Dorival C, Zoulim F, Cagnot C, Decaens T, Thabut D, Asselah T, Mathurin P, Ganne N, Samuel D, Habersetzer F, Bronowicki JP, Guyader D, Rosa I, Leroy V, Chazouilleres O, De Ledinghen V, Bourliere M, Causse X, Cales P, Metivier S, Loustaud-Ratti V, Abergel A, Fontaine H, Carrat F.
PMID: 34699103
Aliment Pharmacol Ther. 2021 Nov;54(10):1364-1365. doi: 10.1111/apt.16661.

No abstract available.

Cite
Pol S, Luzivika Nzinga C, Dorival C, et al. Corrigendum. Aliment Pharmacol Ther. 2021;54(10):1364-1365doi: 10.1111/apt.16661.
Pol, S., Luzivika Nzinga, C., Dorival, C., Zoulim, F., Cagnot, C., Decaens, T., Thabut, D., Asselah, T., Mathurin, P., Ganne, N., Samuel, D., Habersetzer, F., Bronowicki, J. P., Guyader, D., Rosa, I., Leroy, V., Chazouilleres, O., De Ledinghen, V., Bourliere, M., Causse, X., Cales, P., Metivier, S., Loustaud-Ratti, V., Abergel, A., Fontaine, H., Carrat, F. (2021). Corrigendum. Alimentary pharmacology & therapeutics, 54(10), 1364-1365. https://doi.org/10.1111/apt.16661
Pol, Stanislas, et al. "Corrigendum." Alimentary pharmacology & therapeutics vol. 54,10 (2021): 1364-1365. doi: https://doi.org/10.1111/apt.16661
Pol S, Luzivika Nzinga C, Dorival C, Zoulim F, Cagnot C, Decaens T, Thabut D, Asselah T, Mathurin P, Ganne N, Samuel D, Habersetzer F, Bronowicki JP, Guyader D, Rosa I, Leroy V, Chazouilleres O, De Ledinghen V, Bourliere M, Causse X, Cales P, Metivier S, Loustaud-Ratti V, Abergel A, Fontaine H, Carrat F. Corrigendum. Aliment Pharmacol Ther. 2021 Nov;54(10):1364-1365. doi: 10.1111/apt.16661. PMID: 34699103.
Copy Download .nbib Format: NLM
Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities.

JHEP reports : innovation in hepatology

Dong C, Condat B, Picon-Coste M, Chrétien Y, Potier P, Noblinski B, Arrivé L, Hauuy MP, Barbu V, Maftouh A, Gaouar F, Ben Belkacem K, Housset C, Poupon R, Zanditenas D, Chazouillères O, Corpechot C.
PMID: 33554096
JHEP Rep. 2020 Nov 06;3(2):100201. doi: 10.1016/j.jhepr.2020.100201. eCollection 2021 Apr.

BACKGROUND & AIMS: Low-phospholipid-associated cholelithiasis (LPAC) syndrome, a rare genetic form of intrahepatic cholelithiasis in adults, is still poorly understood. We report the results of the largest-ever case-control study of patients with LPAC syndrome aiming to assess the prevalence,...

Cite
Dong C, Condat B, Picon-Coste M, et al. Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. JHEP Rep. 2020;3(2):100201doi: 10.1016/j.jhepr.2020.100201.
Dong, C., Condat, B., Picon-Coste, M., Chrétien, Y., Potier, P., Noblinski, B., Arrivé, L., Hauuy, M. P., Barbu, V., Maftouh, A., Gaouar, F., Ben Belkacem, K., Housset, C., Poupon, R., Zanditenas, D., Chazouillères, O., & Corpechot, C. (2021). Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. JHEP reports : innovation in hepatology, 3(2), 100201. https://doi.org/10.1016/j.jhepr.2020.100201
Dong, Catherine, et al. "Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities." JHEP reports : innovation in hepatology vol. 3,2 (2021): 100201. doi: https://doi.org/10.1016/j.jhepr.2020.100201
Dong C, Condat B, Picon-Coste M, Chrétien Y, Potier P, Noblinski B, Arrivé L, Hauuy MP, Barbu V, Maftouh A, Gaouar F, Ben Belkacem K, Housset C, Poupon R, Zanditenas D, Chazouillères O, Corpechot C. Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. JHEP Rep. 2020 Nov 06;3(2):100201. doi: 10.1016/j.jhepr.2020.100201. eCollection 2021 Apr. PMID: 33554096; PMCID: PMC7848766.
Copy Download .nbib Format: NLM
Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.

Journal of hepatology

Tanaka A, Hirohara J, Nakano T, Matsumoto K, Chazouillères O, Takikawa H, Hansen BE, Carrat F, Corpechot C.
PMID: 33882268
J Hepatol. 2021 Sep;75(3):565-571. doi: 10.1016/j.jhep.2021.04.010. Epub 2021 Apr 18.

BACKGROUND & AIMS: A beneficial effect of bezafibrate (BZF) on symptoms and biochemical features of primary biliary cholangitis (PBC) has been reported in patients with an incomplete response to ursodeoxycholic acid (UDCA), but long-term effects on survival remain unknown....

Cite
Tanaka A, Hirohara J, Nakano T, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021;75(3):565-571doi: 10.1016/j.jhep.2021.04.010.
Tanaka, A., Hirohara, J., Nakano, T., Matsumoto, K., Chazouillères, O., Takikawa, H., Hansen, B. E., Carrat, F., & Corpechot, C. (2021). Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. Journal of hepatology, 75(3), 565-571. https://doi.org/10.1016/j.jhep.2021.04.010
Tanaka, Atsushi, et al. "Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis." Journal of hepatology vol. 75,3 (2021): 565-571. doi: https://doi.org/10.1016/j.jhep.2021.04.010
Tanaka A, Hirohara J, Nakano T, Matsumoto K, Chazouillères O, Takikawa H, Hansen BE, Carrat F, Corpechot C. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021 Sep;75(3):565-571. doi: 10.1016/j.jhep.2021.04.010. Epub 2021 Apr 18. PMID: 33882268.
Copy Download .nbib Format: NLM
Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study.

Clinics and research in hepatology and gastroenterology

Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'Alteroche L, Portal I, Lapidus N, Pol S, Carrat F.
PMID: 33930591
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101713. doi: 10.1016/j.clinre.2021.101713. Epub 2021 Apr 27.

BACKGROUND & AIMS: The factors predicting hepatocellular carcinoma (HCC) occurrence in chronic hepatitis B need to be precisely known to improve its detection. We identified pathways and individual predictive factors associated with HCC in the ANRS CO22 HEPATHER cohort.METHODS:...

Cite
Lam L, Fontaine H, Bourliere M, et al. Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clin Res Hepatol Gastroenterol. 2021;45(5):101713doi: 10.1016/j.clinre.2021.101713.
Lam, L., Fontaine, H., Bourliere, M., Lusivika-Nzinga, C., Dorival, C., Thabut, D., Zoulim, F., Habersetzer, F., Asselah, T., Duclos-Vallee, J. C., Bronowicki, J. P., Mathurin, P., Decaens, T., Ganne, N., Guyader, D., Leroy, V., Rosa, I., De Ledinghen, V., Cales, P., Causse, X., Larrey, D., Chazouilleres, O., Gelu-Simeon, M., Loustaud-Ratti, V., Metivier, S., Alric, L., Riachi, G., Gournay, J., Minello, A., Tran, A., Geist, C., Abergel, A., Raffi, F., D'Alteroche, L., Portal, I., Lapidus, N., Pol, S., Carrat, F. (2021). Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clinics and research in hepatology and gastroenterology, 45(5), 101713. https://doi.org/10.1016/j.clinre.2021.101713
Lam, Laurent, et al. "Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study." Clinics and research in hepatology and gastroenterology vol. 45,5 (2021): 101713. doi: https://doi.org/10.1016/j.clinre.2021.101713
Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'Alteroche L, Portal I, Lapidus N, Pol S, Carrat F. Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101713. doi: 10.1016/j.clinre.2021.101713. Epub 2021 Apr 27. PMID: 33930591.
Copy Download .nbib Format: NLM
New treatments/targets for primary biliary cholangitis.

JHEP reports : innovation in hepatology

Corpechot C, Poupon R, Chazouillères O.
PMID: 32039371
JHEP Rep. 2019 Aug 09;1(3):203-213. doi: 10.1016/j.jhepr.2019.05.005. eCollection 2019 Sep.

Primary biliary cholangitis (PBC) is an autoimmune, cholestatic, chronic liver disease that ultimately progresses towards cirrhosis and liver failure if untreated. While ursodeoxycholic acid has been established as standard of care for PBC in the last few decades, significant...

Cite
Corpechot C, Poupon R, Chazouillères O. New treatments/targets for primary biliary cholangitis. JHEP Rep. 2019;1(3):203-213doi: 10.1016/j.jhepr.2019.05.005.
Corpechot, C., Poupon, R., & Chazouillères, O. (2019). New treatments/targets for primary biliary cholangitis. JHEP reports : innovation in hepatology, 1(3), 203-213. https://doi.org/10.1016/j.jhepr.2019.05.005
Corpechot, Christophe, et al. "New treatments/targets for primary biliary cholangitis." JHEP reports : innovation in hepatology vol. 1,3 (2019): 203-213. doi: https://doi.org/10.1016/j.jhepr.2019.05.005
Corpechot C, Poupon R, Chazouillères O. New treatments/targets for primary biliary cholangitis. JHEP Rep. 2019 Aug 09;1(3):203-213. doi: 10.1016/j.jhepr.2019.05.005. eCollection 2019 Sep. PMID: 32039371; PMCID: PMC7001536.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries